Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
June 01, 2023 09:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases,...
Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
October 20, 2022 08:00 ET
|
Excision BioTherapeutics
Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of viral disease, and the Company’s ongoing Phase 1/2 trial evaluating the...
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
September 29, 2022 07:30 ET
|
Excision BioTherapeutics
CIRM Grant of $6.85 million supports the first-in-human clinical study evaluating the safety and efficacy of EBT-101 in participants people living with HIVEBT-101 is an in vivo CRISPR-based...
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
September 15, 2022 07:00 ET
|
Excision BioTherapeutics
EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs First-in-human study will evaluate the safety and efficacy of EBT-101 in participants...
Excision BioTherapeutics to Present at Upcoming Conferences
September 09, 2022 07:30 ET
|
Excision BioTherapeutics
SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases,...
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET
June 07, 2022 16:05 ET
|
Excision BioTherapeutics
SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced...
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
May 17, 2022 08:00 ET
|
Excision BioTherapeutics
EBT-101 achieves HIV excision without detectable off-target effectsPoster presentation to take place today from 5:30 – 6:30 PM ET SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Excision...
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
January 27, 2022 07:30 ET
|
Excision BioTherapeutics
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE...
Excision BioTherapeutics Expands Management Team with Three Key Appointments
October 12, 2021 08:00 ET
|
Excision BioTherapeutics
Sara Turken, J.D., as General CounselManish Anand, M.Sc., as Senior Vice President, Regulatory AffairsRobert Gunning, CPA, CGMA, as VP, Controller SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- ...
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
September 15, 2021 08:00 ET
|
Excision BioTherapeutics
EBT-101, first-in-human CRISPR-based one-time gene therapy to be evaluated in individuals with HIVInitiation of EBT-101 Phase 1/2 clinical trial expected later this year SAN FRANCISCO, Sept. 15,...